# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Evercore ISI Group analyst Vijay Kumar maintains Danaher (NYSE:DHR) with a Outperform and lowers the price target from $266 ...
https://www.prnewswire.com/news-releases/fda-permits-marketing-of-first-point-of-care-hepatitis-c-rna-test-302185013.html